

# PHARMACY POLICY STATEMENT

## Marketplace

<b>DRUG NAME</b>	<b>Zulresso (brexanolone)</b>
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Zulresso, initially approved in 2019, is a neuroactive steroid gamma aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression (PPD) in patients 15 years and older.

DATE	ACTION/DESCRIPTION
08/12/2019	New policy for Zulresso created.
05/26/2022	Transferred to new template. Updated references. Added site of service and J code. Expanded the type of baseline depression scale acceptable for diagnosis. Added a trial of first-line antidepressants or documentation of PPD severity.
07/08/2022	Lowered age to 15 years old per package insert update.
01/03/2024	Added SNRI as example of antidepressant medication; added that member has not received Zuvavie in the current depressive episode; removed criteria that member cannot be breastfeeding and added criteria that if member is breastfeeding, they have